The Asia-Pacific molecular oncology diagnostics market is experiencing substantial growth fueled by increasing cancer incidence rates, technological advancements, and rising healthcare expenditure. The market is characterized by a heterogeneous landscape of stakeholders, including established multinational corporations and emerging local players. K